The short and long telomere syndromes: Paired paradigms for molecular medicine

Current Opinion in Genetics and Development

Volumn 33, Issue , 2015, Pages 1-9

  Stanley, Susan E ^a,b   Armanios, Mary ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGING; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME SIZE; DISEASE ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC PREDISPOSITION; HUMAN; HUMAN GENETICS; LONG TELOMERE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR CLOCK; MOLECULAR MEDICINE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE; SHORT TELOMERE SYNDROME; TETRAHYMENA THERMOPHILA; TISSUE METABOLISM; GENETICS; MUTATION; NEOPLASM; PATHOLOGY; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

TELOMERASE;

AGING; HUMANS; MOLECULAR MEDICINE; MUTATION; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

EID: 84938086280     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2015.06.004     Document Type: Review

References (92)

1. Blackburn E.H., Gall J.G. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 1978, 120:33-53.
2. Greider C.W., Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985, 43:405-413.
3. Blackburn E.H., Greider C.W., Szostak J.W. Telomeres and telomerase: the path from maize Tetrahymena and yeast to human cancer and aging. Nat Med 2006, 12:1133-1138.
4. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013, 123:996-1002.
5. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
6. Robles-Espinoza C.D., Harland M., Ramsay A.J., Aoude L.G., Quesada V., Ding Z., Pooley K.A., Pritchard A.L., Tiffen J.C., Petljak M., et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 2014, 46:478-481.
7. Shi J., Yang X.R., Ballew B., Rotunno M., Calista D., Fargnoli M.C., Ghiorzo P., Bressac-de Paillerets B., Nagore E., Avril M.F., et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 2014, 46:482-486.
8. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
9. Allsopp R.C., Vaziri H., Patterson C., Goldstein S., Younglai E.V., Futcher A.B., Greider C.W., Harley C.B. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992, 89:10114-10118.
10. Greider C.W. Cellular responses to telomere shortening: cellular senescence as a tumor suppressor mechanism. Harvey Lect 2000, 96:33-50.
11. Greider C.W., Blackburn E.H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987, 51:887-898.
12. Greider C.W., Blackburn E.H. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989, 337:331-337.
13. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
14. Lee H.W., Blasco M.A., Gottlieb G.J., Horner J.W., Greider C.W., DePinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 1998, 392:569-574.
15. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., DePinho R.A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999, 96:701-712.
16. Alder J.K., Guo N., Kembou F., Parry E.M., Anderson C.J., Gorgy A.I., Walsh M.F., Sussan T., Biswal S., Mitzner W., et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011, 184:904-912.
17. Guo N., Parry E.M., Li L.S., Kembou F., Lauder N., Hussain M.A., Berggren P.O., Armanios M. Short telomeres compromise beta-cell signaling and survival. PLoS One 2011, 6:e17858.
18. Armanios M., Alder J.K., Parry E.M., Karim B., Strong M.A., Greider C.W. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 2009, 85:823-832.
19. Greider C.W. Telomerase RNA levels limit the telomere length equilibrium. Cold Spring Harb Symp Quant Biol 2006, 71:225-229.
20. Smogorzewska A., de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem 2004, 73:177-208.
21. Armanios M., Blackburn E.H. The telomere syndromes. Nat Rev Genet 2012, 13:693-704.
22. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
23. Morrison S.J., Prowse K.R., Ho P., Weissman I.L. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 1996, 5:207-216.
24. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994, 91:9857-9860.
25. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
26. Hao L.Y., Armanios M., Strong M.A., Karim B., Feldser D.M., Huso D., Greider C.W. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005, 123:1121-1131.
27. Jonassaint N.L., Guo N., Califano J.A., Montgomery E.A., Armanios M. The gastrointestinal manifestations of telomere-mediated disease. Aging Cell 2013, 12:319-323.
28. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009, 10:45-61.
29. Dietz A.C., Orchard P.J., Baker K.S., Giller R.H., Savage S.A., Alter B.P., Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2010, 46:98-104.
30. Silhan L.L., Shah P.D., Chambers D.C., Snyder L.D., Riise G.C., Wagner C.L., Hellstrom-Lindberg E., Orens J.B., Mewton J.F., Danoff S.K., et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014, 44:178-187.
31. Vulliamy T., Marrone A., Dokal I., Mason P.J. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002, 359:2168-2170.
32. Dokal I. Inherited aplastic anaemia. Hematol J 2003, 4:3-9.
33. Yamaguchi H., Baerlocher G.M., Lansdorp P.M., Chanock S.J., Nunez O., Sloand E., Young N.S. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003, 102:916-918.
34. Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M., Chanock S.J., Lansdorp P.M., Young N.S. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005, 352:1413-1424.
35. Alder J.K., Stanley S.E., Wagner C.L., Hamilton M., Hanumanthu V.S., Armanios M. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2014, 147:1361-1368.
36. Heiss N.S., Knight S.W., Vulliamy T.J., Klauck S.M., Wiemann S., Mason P.J., Poustka A., Dokal I. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998, 19:32-38.
37. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
38. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110:768-779.
39. de la Fuente J., Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007, 11:584-594.
40. Glousker G., Touzot F., Revy P., Tzfati Y., Savage S.A. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol 2015, [epub May 4, 2015].
41. Hoyeraal H.M., Lamvik J., Moe P.J. Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr Scand 1970, 59:185-191.
42. Hreidarsson S., Kristjansson K., Johannesson G., Johannsson J.H. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr Scand 1988, 77:773-775.
43. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 2012, 730:52-58.
44. Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G., Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326.
45. Alder J.K., Parry E.M., Yegnasubramanian S., Wagner C.L., Lieblich L.M., Auerbach R., Auerbach A.D., Wheelan S.J., Armanios M. Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat 2013, 34:1481-1485.
46. Alder J.K., Stanley S.E., Wagner C.L., Hamilton M., Hanumanthu V.S., Armanios M. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2015, 147:1361-1368.
47. Cogan J.D., Kropski J.A., Zhao M., Mitchell D.B., Rives L., Markin C., Garnett E.T., Montgomery K.H., Mason W.R., McKean D.F., et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 2015, 191:646-655.
48. Stuart B.D., Choi J., Zaidi S., Xing C., Holohan B., Chen R., Choi M., Dharwadkar P., Torres F., Girod C.E., et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 2015, 47:512-517.
49. Kropski J.A., Mitchell D.B., Markin C., Polosukhin V.V., Choi L.A., Johnson J.E., Lawson W.E., Phillips J.A., Cogan J.D., Blackwell T.S., et al. A novel dyskerin (DKC1) mutation is associated with Familial Interstitial Pneumonia. Chest 2014, 146:e1-e7.
50. Stanley S.E., Chen J.J., Podlevsky J.D., Alder J.K., Hansel N.N., Mathias R.A., Qi X., Rafaels N.M., Wise R.A., Silverman E.K., et al. Telomerase mutations in smokers with severe emphysema. J Clin Invest 2015, 125:563-570.
51. Alder J.K., Barkauskas C.E., Limjunyawong N., Stanley S.E., Kembou F., Tuder R.M., Hogan B.L., Mitzner W., Armanios M. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci U S A 2015, 112:5099-5104.
52. Raghu G., Weycker D., Edelsberg J., Bradford W.Z., Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816.
53. Castaldi P.J., Dy J., Ross J., Chang Y., Washko G.R., Curran-Everett D., Williams A., Lynch D.A., Make B.J., Crapo J.D., et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax 2014, 69:415-422.
54. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557.
55. Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P., Kelly R., Stewart A., Bowen D., Schonland S.O., et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009, 30:1567-1573.
56. Vulliamy T., Marrone A., Goldman F., Dearlove A., Bessler M., Mason P.J., Dokal I. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001, 413:432-435.
57. Armanios M., Chen J.L., Chang Y.P., Brodsky R.A., Hawkins A., Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A., et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005, 102:15960-15964.
58. Vulliamy T., Beswick R., Kirwan M., Marrone A., Digweed M., Walne A., Dokal I. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 2008, 105:8073-8078.
59. Walne A.J., Vulliamy T., Marrone A., Beswick R., Kirwan M., Masunari Y., Al-Qurashi F.H., Aljurf M., Dokal I. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007, 16:1619-1629.
60. Savage S.A., Giri N., Baerlocher G.M., Orr N., Lansdorp P.M., Alter B.P. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509.
61. Kocak H., Ballew B.J., Bisht K., Eggebeen R., Hicks B.D., Suman S., O'Neil A., Giri N., Maillard I., Alter B.P., et al. Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1. Genes Dev 2014, 28:2090-2102.
62. Guo Y., Kartawinata M., Li J., Pickett H.A., Teo J., Kilo T., Barbaro P.M., Keating B., Chen Y., Tian L., et al. Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1. Blood 2014, 124:2767-2774.
63. Tummala H., Walne A., Collopy L., Cardoso S., de la Fuente J., Lawson S., Powell J., Cooper N., Foster A., Mohammed S., et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J Clin Invest 2015, 125:2151-2160.
64. Ballew B.J., Yeager M., Jacobs K., Giri N., Boland J., Burdett L., Alter B.P., Savage S.A. Germline mutations of regulator of telomere elongation helicase 1 RTEL1, in Dyskeratosis congenita. Hum Genet 2013, 132:473-480.
65. Walne A.J., Vulliamy T., Kirwan M., Plagnol V., Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am J Hum Genet 2013, 92:448-453.
66. Le Guen T., Jullien L., Touzot F., Schertzer M., Gaillard L., Perderiset M., Carpentier W., Nitschke P., Picard C., Couillault G., et al. Human RTEL1 deficiency causes Hoyeraal-Hreidarsson syndrome with short telomeres and genome instability. Hum Mol Genet 2013, 22:3239-3249.
67. Zhong F., Savage S.A., Shkreli M., Giri N., Jessop L., Myers T., Chen R., Alter B.P., Artandi S.E. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenital. Genes Dev 2011, 25:11-16.
68. Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011, 117:5607-5611.
69. Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R., Vulliamy T., Dokal I. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007, 110:4198-4205.
70. Stanley S.E., Noth I., Armanios M. What the genetics "RTEL"ing us about telomeres and pulmonary fibrosis. Am J Respir Crit Care Med 2015, 191:608-610.
71. Vulliamy T., Marrone A., Szydlo R., Walne A., Mason P.J., Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36:447-449.
72. Alder J.K., Cogan J.D., Brown A.F., Anderson C.J., Lawson W.E., Lansdorp P.M., Phillips J.A., Loyd J.E., Chen J.J., Armanios M. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 2011, 7:e1001352.
73. Aoude L.G., Pritchard A.L., Robles-Espinoza C.D., Wadt K., Harland M., Choi J., Gartside M., Quesada V., Johansson P., Palmer J.M., et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 2015, 107.
74. Bainbridge M.N., Armstrong G.N., Gramatges M.M., Bertuch A.A., Jhangiani S.N., Doddapaneni H., Lewis L., Tombrello J., Tsavachidis S., Liu Y., et al. Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 2015, 107:384.
75. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
76. Bell R.J., Rube H.T., Kreig A., Mancini A., Fouse S.F., Nagarajan R.P., Choi S., Hong C., He D., Pekmezci M., et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015, 348:1036-1039.
77. Heidenreich B., Rachakonda P.S., Hemminki K., Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev 2014, 24:30-37.
78. Nandakumar J., Bell C.F., Weidenfeld I., Zaug A.J., Leinwand L.A., Cech T.R. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature 2012, 492:285-289.
79. Wang F., Podell E.R., Zaug A.J., Yang Y., Baciu P., Cech T.R., Lei M. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 2007, 445:506-510.
80. Ye J.Z., Hockemeyer D., Krutchinsky A.N., Loayza D., Hooper S.M., Chait B.T., de Lange T. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev 2004, 18:1649-1654.
81. Aviv A. Genetics of leukocyte telomere length and its role in atherosclerosis. Mutat Res 2012, 730:68-74.
82. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
83. Rudolph K.L., Millard M., Bosenberg M.W., DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001, 28:155-159.
84. Perera S.A., Maser R.S., Xia H., McNamara K., Protopopov A., Chen L., Hezel A.F., Kim C.F., Bronson R.T., Castrillon D.H., et al. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 2008, 29:747-753.
85. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G.J., Singer R.H., Greider C.W., DePinho R.A. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999, 97:515-525.
86. Feldser D.M., Hackett J.A., Greider C.W. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 2003, 3:623-627.
87. Iles M.M., Bishop D.T., Taylor J.C., Hayward N.K., Brossard M., Cust A.E., Dunning A.M., Lee J.E., Moses E.K., Akslen L.A., et al. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 2014, 106.
88. Burke L.S., Hyland P.L., Pfeiffer R.M., Prescott J., Wheeler W., Mirabello L., Savage S.A., Burdette L., Yeager M., Chanock S., et al. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 2013, 8:e71121.
89. Llorca-Cardenosa M.J., Pena-Chilet M., Mayor M., Gomez-Fernandez C., Casado B., Martin-Gonzalez M., Carretero G., Lluch A., Martinez-Cadenas C., Ibarrola-Villava M., et al. Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk. Eur J Cancer 2014, 50:3168-3177.
90. Nan H., Du M., De Vivo I., Manson J.E., Liu S., McTiernan A., Curb J.D., Lessin L.S., Bonner M.R., Guo Q., et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011, 71:6758-6763.
91. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
92. Anic G.M., Sondak V.K., Messina J.L., Fenske N.A., Zager J.S., Cherpelis B.S., Lee J.H., Fulp W.J., Epling-Burnette P.K., Park J.Y., et al. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol 2013, 37:434-439.